UniProtKB/SwissProt variant VAR

Variant information

Variant position:

153

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:

LP/P [Disclaimer]

The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Cysteine (C) to Tyrosine (Y) at position 153 (C153Y, p.Cys153Tyr).

Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:

Change from medium size and polar (C) to large size and aromatic (Y)

The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:

-2

The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page

Variant description:

In RBMX1B.

Any additional useful information about the variant.

Other resources:

Links to websites of interest for the variant.

Variant rs122458145 [ dbSNP | Ensembl ]

Sequence information

Variant position:

153

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:

323

The length of the canonical sequence.

Location on the sequence:

KQVIGTGSFFPKGEDFYCVT C HETKFAKHCVKCNKAITSGG

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         KQVI----------GTGSFFPKGEDF-----------------------YCVTCHETKFAK------------------------HCVKCNKAITSGG

Mouse                         KQVI----------GTGSFFPKGEDF---------------

Rat                           KQVI----------GTGSFFPKGEDF---------------

Baker's yeast                 NKSF----RKVSKEGKGWLWGLDEEYIAERERQKKKQSEIA

Fission yeast                 NKAFIRIPRRQNEPGKGSFWMLDPSYIDQFEGNFFRRTKKP

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	2 – 323	Four and a half LIM domains protein 1
Domain	101 – 153	LIM zinc-binding 2
Helix	151 – 157

Literature citations

Proteomic identification of FHL1 as the protein mutated in human reducing body myopathy.
Schessl J.; Zou Y.; McGrath M.J.; Cowling B.S.; Maiti B.; Chin S.S.; Sewry C.; Battini R.; Hu Y.; Cottle D.L.; Rosenblatt M.; Spruce L.; Ganguly A.; Kirschner J.; Judkins A.R.; Golden J.A.; Goebel H.-H.; Muntoni F.; Flanigan K.M.; Mitchell C.A.; Boennemann C.G.;
J. Clin. Invest. 118:904-912(2008)
Cited for: INVOLVEMENT IN RBMX1A; INVOLVEMENT IN RBMX1B; VARIANTS RBMX1A TYR-123 AND PHE-132; VARIANTS RBMX1B TYR-153 AND ARG-153;

Clinical, histological and genetic characterization of reducing body myopathy caused by mutations in FHL1.
Schessl J.; Taratuto A.L.; Sewry C.; Battini R.; Chin S.S.; Maiti B.; Dubrovsky A.L.; Erro M.G.; Espada G.; Robertella M.; Saccoliti M.; Olmos P.; Bridges L.R.; Standring P.; Hu Y.; Zou Y.; Swoboda K.J.; Scavina M.; Goebel H.H.; Mitchell C.A.; Flanigan K.M.; Muntoni F.; Boennemann C.G.;
Brain 132:452-464(2009)
Cited for: VARIANTS RBMX1A GLN-123; LEU-123; TYR-123 AND PHE-132; VARIANTS RBMX1B ARG-153 AND TYR-153;

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q13642: Variant p.Cys153Tyr